NeuBase Therapeutics, Inc. (NASDAQ:NBSE – Get Rating) – Analysts at Oppenheimer issued their Q1 2023 EPS estimates for NeuBase Therapeutics in a note issued to investors on Tuesday, January 10th. Oppenheimer analyst H. Singh anticipates that the company will post earnings per share of ($0.11) for the quarter. Oppenheimer currently has a “Market Perform” rating on the stock. The consensus estimate for NeuBase Therapeutics’ current full-year earnings is ($0.95) per share. Oppenheimer also issued estimates for NeuBase Therapeutics’ Q2 2023 earnings at ($0.10) EPS, Q3 2023 earnings at ($0.08) EPS, Q4 2023 earnings at ($0.09) EPS, FY2023 earnings at ($0.32) EPS, FY2024 earnings at ($0.33) EPS, FY2025 earnings at ($0.46) EPS and FY2026 earnings at ($0.65) EPS.
Other analysts also recently issued research reports about the stock. Chardan Capital downgraded shares of NeuBase Therapeutics from a “buy” rating to a “neutral” rating in a research report on Monday, October 17th. Royal Bank of Canada downgraded shares of NeuBase Therapeutics from an “outperform” rating to a “sector perform” rating in a research report on Tuesday, October 18th.
NeuBase Therapeutics Trading Up 2.8 %
Hedge Funds Weigh In On NeuBase Therapeutics
Hedge funds have recently added to or reduced their stakes in the business. First Manhattan Co. acquired a new position in NeuBase Therapeutics in the first quarter worth $26,000. Perkins Capital Management Inc. boosted its holdings in NeuBase Therapeutics by 22.6% in the second quarter. Perkins Capital Management Inc. now owns 81,500 shares of the company’s stock worth $86,000 after purchasing an additional 15,000 shares during the period. Renaissance Technologies LLC boosted its holdings in shares of NeuBase Therapeutics by 20.2% during the third quarter. Renaissance Technologies LLC now owns 287,386 shares of the company’s stock valued at $114,000 after acquiring an additional 48,255 shares during the period. State Street Corp boosted its holdings in shares of NeuBase Therapeutics by 18.4% during the first quarter. State Street Corp now owns 68,687 shares of the company’s stock valued at $129,000 after acquiring an additional 10,674 shares during the period. Finally, CM Management LLC boosted its holdings in shares of NeuBase Therapeutics by 21.6% during the third quarter. CM Management LLC now owns 450,000 shares of the company’s stock valued at $178,000 after acquiring an additional 80,000 shares during the period. Institutional investors and hedge funds own 37.21% of the company’s stock.
NeuBase Therapeutics Company Profile
NeuBase Therapeutics, Inc, a preclinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The company's proprietary modular peptide-nucleic acid antisense oligo (PATrOL) platform focuses on addressing Huntington's disease (HD) and myotonic dystrophy, as well as other genetic disorders, and cancer and oncology applications.
- Get a free copy of the StockNews.com research report on NeuBase Therapeutics (NBSE)
- Exxon Mobil Expects Earnings and Cash Flow to Grow
- Sorrento Therapeutics, Scilex: 2 Hot Pharma Stocks On the Move
- Is The Great Alibaba Recovery About To Begin?
- KB Home, Another Reason To Shed Home Building Stocks
- Is Wendy’s Stock Uptrend Set To Continue?
Receive News & Ratings for NeuBase Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuBase Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.